KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Cost of Revenue (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Cost of Revenue readings, the most recent being $696.0 million for Q1 2026.

  • On a quarterly basis, Cost of Revenue rose 11.9% to $696.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.0 billion, a 39.3% decrease, with the full-year FY2025 number at $8.3 billion, down 1.9% from a year prior.
  • Cost of Revenue hit $696.0 million in Q1 2026 for Teva Pharmaceutical Industries, down from $2.1 billion in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $6.6 billion in Q4 2024 to a low of $539.0 million in Q3 2022.
  • Median Cost of Revenue over the past 5 years was $2.1 billion (2025), compared with a mean of $1.9 billion.
  • Biggest five-year swings in Cost of Revenue: tumbled 71.13% in 2023 and later surged 980.33% in 2024.
  • Teva Pharmaceutical Industries' Cost of Revenue stood at $2.1 billion in 2022, then tumbled by 71.13% to $610.0 million in 2023, then surged by 980.33% to $6.6 billion in 2024, then crashed by 68.8% to $2.1 billion in 2025, then plummeted by 66.15% to $696.0 million in 2026.
  • The last three reported values for Cost of Revenue were $696.0 million (Q1 2026), $2.1 billion (Q4 2025), and $2.2 billion (Q3 2025) per Business Quant data.